Q1 FY27 Results: Revenue up 30%, PAT more than doubles YoY

Revenue growth above 20%Profit growth above 25%EBITDA margin expansionEmphasis of matterResults View source PDF Explain this filing

VENUSREM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+5.7%Reaction day

₹1682.20

prior close

₹1621.10

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.3%+5.4% vs market

Pharmaceuticals peers, median of 165sector+0.1%+5.6% vs sector

On the reaction day the stock moved 5.4 pts more than Nifty Microcap 250 and 5.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+7.5

10m

+9.7

15m

+9.7

30m

+9.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+5.7+0.3+5.4+0.1+5.6

Next day

+0.3-0.9+1.1-1.5+1.8

-1.9-1.5-0.4-2.1+0.2

-2.1-1.1-1.0-2.3+0.2

-6.5+0.2-6.7-1.5-5.0

-8.8-1.1-7.7-2.2-6.5

-8.5-1.2-7.3-2.6-5.9

15d

-6.1+3.1-9.3+0.3-6.5

+3.8+4.5-0.6-0.7+4.6

-5.6+4.5-10.1+1.3-6.9

-10.0-2.2-7.7-5.8-4.2

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Venus Remedies posted strong Q1 FY27 results. Standalone revenue rose to Rs 178.80 Cr from Rs 137.13 Cr, about 30 percent YoY growth. Net profit surged to Rs 25.53 Cr from Rs 11.70 Cr, more than doubling. EBITDA climbed to Rs 39.11 Cr. Consolidated PAT at Rs 22.97 Cr versus Rs 9.60 Cr. Board also approved revisions to MOA and AOA. Auditor flagged emphasis of matter on Rs 28.60 Cr outstanding share application money in German subsidiary Venus Pharma GmbH undergoing restructuring.

Likely market impact

Strong Q1 with revenue and PAT both showing robust YoY growth. Watch for recovery of German subsidiary exposure and AGM outcome on MOA changes.